NSCLC Drug Universe Expands: Genentech's Alecensa OK'd
This article was originally published in Scrip
The universe seems to be working this year in favor of patients with non-small-cell lung cancer (NSCLC) – with a lot of help from drug makers and the FDA's Office of Hematology and Oncology Products.
You may also be interested in...
Roche’s Alecensa gets EU nod for second-line use in ALK+ non-small cell lung cancer patients – but first-line data in 2017 will be vital.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.